Results for Pathophysiology

Dr. Levy is the director of Cardiology Research, and also serves as program director of the Cardiology National Heart, Lung, and Blood Institute (NHLBI) Research Training Grant. His research interests are the pathophysiology of biomaterials used in medicine, basic mechanisms and novel therapies for heart valve disease, arterial angioplasty, local drug delivery, and nanomedicine. He also has experience over three decades in medical device development.

Dr. De Leon-Crutchlow’s translational research program focuses on examining the pathophysiology of disorders of insulin regulation, identifying novel therapeutic targets, and developing new therapies for these conditions. The program approach includes patient-oriented research and bench research employing mouse models and primary islet cultures.

Dr. Rivella is an expert in the pathophysiology of erythroid and iron disorders and in the generation of lentiviral vectors for the cure of hemoglobinopathies. He also investigates additional disorders such as anemia of inflammation and hemochromatosis.

Dr. Shah's research is centered on understanding obesity and its related complications. Her current work includes clinical and translational studies exploring pathophysiology and modulation of obesity-related adipose tissue and systemic inflammation using human cell lines and clinical trials. She is also involved in clinical studies of outcomes and risk factors of polycystic ovarian syndrome and type 2 diabetes in teens.

Dr. Chou investigates the mechanisms of normal hematopoietic development and how these become disrupted in hematologic diseases.

Dr. Hamilton studies intestinal epithelial cells and how they help maintain human health. Although there is a great deal understood about how these cells function, little is known about how they behave during disease. Dr. Hamilton focuses on defining new mechanisms in regenerative medicine, inflammatory bowel disease, and colorectal cancer.

Dr. Van Batavia's long-term goal is to become a leader in neuro-urology and lower urinary tract dysfunction, with particular emphasis on deciphering the pathophysiology of lower urinary tract dysfunction and translating developments in the basic science arena into clinical improvements for patients.

Dr. Bauer's academic and clinical career are focused on improving the care of children and adolescents with thyroid disease. He has extensive experience and knowledge of thyroid pathophysiology and tumorigenesis, and has been critical to the clinical success of the Children's Hospital of Philadelphia Thyroid Center.

Dr. Koyama's research focuses on Hereditary Multiple Exostoses (HME), a genetic disorder that causes the development of multiple benign tumors on the surface of the metaphyses of long bones. Based on his extensive knowledge of the normal processes of skeletal development and growth, Dr. Koyama's research aims to clarify the molecular mechanisms of HME formation and growth.

Bone disorders exact a considerable toll on human health in both children and adults. Dr. Long seeks to understand the fundamental mechanisms underlying both normal skeletal development and the pathophysiology of bone diseases. His current research includes studies of skeletal stem cells and progenitors, metabolic regulation of bone cells, and the integration of bone and whole-body metabolism.